All Alchemab Therapeutics Ltd articles
-
ArticleLet’s talk neuroscience with Michelle Sidor at SFN
Drug Target Review’s Taylor Mixides met with Dr Michelle Sidor, the Director of Neuroscience at Alchemab Therapeutics, and Dr Sifis Pediaditakis at the Society for Neuroscience event this November. This exclusive interview explores neuroscientific research and its pivotal role in steering the company toward future triumphs. Michelle highlights the dynamic ...
-
ArticleHuntington's disease and potential therapies
In this exclusive interview with Young Kwon, CEO of Alchemab, we discuss new platforms that are revolutionising how researchers identify naturally occurring antibodies in resilient individuals, opening up new possibilities for the development of disease-modifying therapies.
-
ArticleNavigating the challenges and opportunities of AI in drug development and personalised medicine
This article is the second part of Drug Target Review’s Izzy Wood’s discussion with Olivia Cavlan, Chief Corporate Development and Strategy Officer at Alchemab Therapeutics Ltd, exploring the role of AI in target discovery, its applications in personalised medicine, and the evolving landscape of pharmaceutical development.